Lisata Therapeutics (NASDAQ:LSTA) reported quarterly losses of $(7.88) per share. This is a 352.87 percent decrease over losses of $(1.74) per share from the same period last year.
Huntington CEO Upbeat On 2024 Prospects Despite Missing Q4 Revenue Estimates, Projects ‘Attractive Growth Opportunities’
Huntington Bancshares' net interest income drops 10% YoY to $1.316 billion. Noninterest income also decreases 19% to $405 million. Adjusted EPS aligns with consensus at $0.27.
